2016 CurePSP International Research Symposium
October 27, Jersey City, NJ — Starting with a networking session on the evening of Thursday, October 27, and following with a full day of speakers on Friday the 28th, the 2016 International Research Symposium has surpassed all expectations. A record 148 registrants, with some coming from countries as far away as Japan, filled available capacity. The speakers present were carefully selected for their outstanding work in leading the field of tau research.
“We were so excited to have doubled the attendance of last year’s symposium. The energy of the researchers and clinicians is palpable,” said Jaclyn Zendrian, CurePSP Director of Events. “This momentum will see this event become a yearly calendar standout in neurology.”
Friday’s speakers included Dr. Justin Ichida of the University of Southern California, Dr. Sally Temple of the Neural Stem Cell Institute, CurePSP board member and PSP Genetics Consortium Managing Director Dr. Jeffrey Friedman, Dr. Dianna Wheaton of the FTD Disorders Registry, Dr. Lawrence Golbe of Rutgers University, Dr. Dennis Dickson from the Mayo Clinic, and Dr. Karen Duff of Columbia University, to name only a few.
All of these speakers are widely recognized as leaders in their fields.
“We are very pleased to see that the CurePSP International Research Symposium is becoming a premier event in the field of neurodegeneration research,” said David Kemp, President of CurePSP. “We are greatly appreciative of our sponsors, AbbVie, Bristol-Myers Squibb and Merck, and to the Light of Day Foundation for their continuing support.”
“This symposium has brought together the best minds in neurodegenerative science from quite a few countries, and the presenters were an excellent caliber,” said Dr. Alex Klein, Vice President – Scientific Affairs. “This interest in neurodegeneration has a huge momentum behind it, and I can see this symposium being even bigger next year, bringing the key players in neurodegeneration research together to find a cure for these devastating prime of life brain diseases.”